Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 157, Issue 2, Pages 249-269Publisher
SPRINGER
DOI: 10.1007/s11060-022-03977-x
Keywords
HER2 breast cancer; Brain metastases; Leptomeningeal disease; Radiation therapy
Categories
Ask authors/readers for more resources
Patients with HER2-positive breast cancer are at a high risk of breast cancer brain metastasis and leptomeningeal disease. The management of these cases is rapidly evolving and requires a multidisciplinary approach. Advances in systemic therapy have improved survival, and ongoing clinical trials are investigating potential targeted therapies.
Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal disease (LMD). Improvements in systemic therapy have translated to improved survival for patients with HER2-positive BCBM and LMD. However, the optimal management of these cases is rapidly evolving and requires a multidisciplinary approach. Herein, a team of radiation oncologists, medical oncologists, neuro-oncologists, and breast surgeon created a review of the evolving management of HER2-positive BCBM and LMD. We assess the epidemiology, diagnosis, and evolving treatment options for patients with HER2-positive BCBM and LMD, as well as the ongoing prospective clinical trials enrolling these patients. The management of HER2-positive BCBM and LMD represents an increasingly common challenge that involves the coordination of local and systemic therapy. Advances in systemic therapy have resulted in an improved prognosis, and promising targeted therapies currently under prospective investigation have the potential to further benefit these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available